Do GLP-1 Drugs Cause Muscle and Joint Side Effects? Meta-Analysis of RCTs | Research

The takeaway

Systematic review and meta-analysis of RCT safety data assesses whether GLP-1 receptor agonists are associated with musculoskeletal adverse events.

RCT safety meta-analysis
Musculoskeletal adverse events assessed across GLP-1 RA clinical trials

What the researchers found

Systematic review and meta-analysis of RCT safety data evaluates the association between GLP-1 RA use and spontaneous reports of musculoskeletal adverse events.

Why it matters

Millions take GLP-1 drugs, and muscle/joint complaints are common patient concerns. Evidence-based safety data helps clinicians provide informed counseling.

How the study worked

Systematic review and meta-analysis of randomized controlled trials assessing musculoskeletal adverse event reports in GLP-1 RA-treated patients.

What this study cannot tell us

Relies on spontaneous adverse event reporting in RCTs, which may undercount real-world events. Different musculoskeletal conditions may have different risk profiles.

How to read the evidence

Systematic review and meta-analysis of RCT safety data — high-quality evidence for adverse event assessment.

When this study was published

Published in 2026; comprehensive musculoskeletal safety review of GLP-1 drugs.

The bigger picture

As GLP-1 drugs become among the most prescribed medications globally, comprehensive safety profiling across all organ systems is essential.

Questions still open

Does GLP-1-induced weight loss reduce or increase musculoskeletal problems overall?
Are specific GLP-1 agents more associated with musculoskeletal events than others?

Common questions

Do GLP-1 drugs cause joint or muscle pain?

This meta-analysis of clinical trial safety data evaluates the evidence. While some patients report musculoskeletal symptoms, rapid weight loss itself can also affect joints and muscles regardless of the method used.

Should I worry about bone loss on GLP-1 drugs?

Rapid weight loss from any cause can affect bone density. This analysis helps quantify whether GLP-1 drugs specifically add musculoskeletal risk beyond what weight loss alone would cause.

Read the original research

The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.

Therapeutic advances in musculoskeletal disease, 18, 1759720X261428147

View on PubMed ↗Publisher’s paper ↗

Citation

Cao, Meng; Lin, Chu; Cai, Xiaoling; Lv, Fang; Yang, Wenjia; Ji, Linong. (2026). The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.. Therapeutic advances in musculoskeletal disease, 18, 1759720X261428147. https://doi.org/10.1177/1759720X261428147